Scientists zap brain to unlock secrets of smell
NCT ID NCT07099092
First seen Jun 24, 2026 · Last updated Sep 21, 2026 · Updated 60 times
Summary
This study uses a gentle ultrasound technique to temporarily change activity in brain areas linked to smell. Researchers want to understand how odors influence our actions. Eighty healthy adults aged 18-45 will do computer tasks while smelling different scents, with brain scans and body sensors tracking responses. This is basic science, not a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2035
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet the following criteria: 1. Aged 18-45 years old. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in the measured signals. 2. In good general health based on the assessment of the Medical Advisory Investigator (MAI) or delegate. 3. Right-handed. EXCLUSION CRITERIA: Individuals who meet any of the following criteria will be excluded from participation: 1. Any neurological disorder that would increase seizure risk from TUS such as stroke, brain lesions, previous neurosurgery, epilepsy, any history of seizure or fainting episode of unknown cause, frequent severe headache, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than one month. The MAI will also retain discretion to exclude based on a history of a neurological illness or trauma that may compromise safety or data integrity. 2. Predisposition to seizures (e.g., first-degree family history of potentially hereditary epilepsy, etc.). 3. Current use (any use in the past week, daily use for more than one week within past 3 months) of any investigational drug or of any medications with psychotropic (e.g., benzodiazepines, etc.), or anti or pro-convulsive action. This will be determined at the discretion of the MAI. 4. Unable to undergo MRI, or TUS due to certain metallic or magnetic devices or implants in the body, claustrophobia, or other reasons including numbness or paresthesia of the head. 5. History of noise-induced hearing loss or tinnitus. 6. Recent history (within past 12 months) of learning disability, major DSM-5 psychiatric disorder including major affective disorder, ADHD, obsessivecompulsive disorder, schizophrenia, or PTSD. This will be determined at the discretion of the MAI. 7. Pattern of alcohol and drug use in the past 12 months that is indicative of harmful use, loss of control over use, or physical dependence. 8. Daily nicotine, alcohol, or drug use (excluding caffeine) for at least 4 continuous weeks within the past 12 months. 9. Participation in any neuromodulation (e.g., TMS, TUS, tDCS, tACS, etc.) session (excluding the current protocol) in the past two weeks. 10. History of anaphylaxis and/or severe food and non-food allergies (e.g., latex, detergents, soap, etc.). 11. History of significant chronic obstructive pulmonary disease (COPD) or severe, uncontrolled asthma, as increased levels of carbon dioxide may increase the susceptibility to cavitation and related tissue damage. 12. Uncorrected impairments in visual acuity severe enough to affect task participation. 13. Non-English speaking. Justification: Data integrity of some of the behavioral tasks used in this study would be compromised as they have only been validated in English. Most importantly, ongoing communication regarding safety procedures is necessary when participants are undergoing TUS and MRI procedures. The inability to effectively communicate TUS and MRI safety procedures in a language other than English could compromise the safety of non-English speaking participants. 14. Serious skin disease involving the hands or head, or history of serious systemic allergy involving the skin or mucous membranes such as Stevens-Johnson syndrome, or known history of contact dermatitis to ultrasound gel. Justification: Gel will be applied to the skin on both head and hands, for transducer coupling and electrode placement, respectively. Allergic or adverse reactions to such treatment need to be ruled out. 15. Hyposmia, i.e., decreased sense of smell, or anosmia, i.e., loss of smell (Sniffin' Sticks Olfactory Identification Score \< 10). Justification: The ability to smell is paramount to task performance. 16. Pregnancy. Justification: It is unknown whether MRI and/or TUS pose risks to fetuses. 17. Any other condition that in the judgment of the investigators is incompatible with participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Normal physiology are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
National Institute on Drug Abuse
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your pupils reveal how light shapes sleep—and why age and sex matter
- Healthy donors needed for research sample bank
- Nicotine's brain impact on depression under the microscope
- Scientists lock volunteers in rooms to measure how many calories they burn after eating
- Brain test could revolutionize alcohol addiction treatment
- Healthy brains scanned twice to test reliability of imaging methods